

Discoveries in gene-environment interactions that influence CVD, lipid traits, obesity, diabetes, and hypertension appear to be able to influence gene therapy.

Moataz Dowaidar ^{1,2}

¹ Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia.

² Interdisciplinary Research Center for Hydrogen and Energy Storage (IRC-HES), King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, 31261, Saudi Arabia.

Abstract

In a relatively short amount of time, significant progress has been made in discovering gene-environment interactions that influence CVD, lipid traits, obesity, diabetes, and hypertension. These correlations appear to change genetic vulnerability, which may help researchers better understand the genetic processes that influence CVD development in the future. In order to advance the field, further research is required to confirm initial comparisons, identify the biological processes by which environmental influences modify genetic risk, and investigate strategies that use this knowledge to influence clinical genetic therapy outcomes.

The leading cause of morbidity and death in the world is cardiovascular disease (CVD). 1 The majority of CVD cases are caused by modifiable risk factors including diabetes, asthma, obesity, dyslipidemia, smoking, lifestyle factors, psychosocial stressors, alcohol intake levels, and physical inactivity, which account for more than 90% of MI cases and more than 80% of stroke cases worldwide. 2 and 3 Despite the fact that CVD prevalence is decreasing in high-income countries, it is rising in many low-and middle-income countries as a result of rapid lifestyle changes, growth, and urbanization. Such noncommunicable cardiometabolic disorders, such as obesity, hypertension, and diabetes, have also increased as a result of these shifts. 4 and 5 Several ethnic groups in Canada, including South Asians, Aboriginals, Chinese, and Afro-Caribbeans, are at risk of contracting cardiometabolic diseases. 6 To reduce global CVD pressure, individual and population-level interventions aimed at improving modifiable cardiovascular risk factors are needed.

Our awareness of CVD is becoming increasingly genetically informed. Many genetic variants linked to increased CVD risk have recently been discovered in genome-wide interaction studies (GWAS), showing that CVD is a nuanced disorder with polygenic and environmental effects. 7, 8 Single nuclear polymorphisms (SNPs) have been shown to affect the progression of coronary artery disease (CAD), with all of them inducing atherosclerosis by mechanisms unrelated to typical risk factors. 9 other polymorphisms have been linked to lipid characteristics, diabetes, obesity, and hypertension. We are just beginning to comprehend the impact of genetics on cardiovascular disease, including how genetic and modifiable risk factors combine to affect cardiovascular risk.

When behavioural factors (such as smoking, physical exercise, or nutritional factors) alter the association between genetic polymorphisms and phenotypic characteristics, this is known as a gene-environment interaction. Some intriguing findings indicate that environmental conditions may alter the genetic risks associated with a variety of cardiometabolic diseases. Gene-environment interactions could lead to the discovery of new pathways in the production of CVD, as well as a better understanding of how genetic factors influence cardiovascular risk. Though the most exciting opportunity for this area of study is the use of gene-environment associations to guide possible "personalized" approaches to treatment, this application has yet to be proved. Several analytical hurdles must be solved in order to properly assess the therapeutic efficacy of these experiences.

Furthermore, although certain associations have been reliably found in different cultures, the majority of them have not been adequately replicated. This review look at the current state of knowledge about gene-environment interactions in CAD, obesity, diabetes, hypertension, and lipid metabolism, as well as the conceptual hurdles that must be addressed in order to advance cardiovascular gene-environment science.

The majority of GWAS-identified polymorphisms increase MI risk in small to moderate ways, accounting for around 10% of the inherited variance in disease growth.7, 9 As a result, the majority of heritable CAD risk remains unaccounted for, which may be clarified by alternate genetic mechanisms such as gene-environment interactions, gene-gene interactions, and unusual polymorphisms with significant effects or genetic variations with limited effects that are difficult to diagnose with current techniques.

Polymorphisms in the 9p21 chromosomal region have been linked to a variety of CVD symptoms. 18 The 9p21 mutation is widespread (up to 50% of people in certain ethnic groups carry a risk allele) and one of the most powerful genetic predictors of CAD, raising CAD risk by 1.20 to 1.29 times per risk allele. 7 and 8

About its strong link to vascular risk, the mechanisms by which 9p21 acts remain largely unclear. Polymorphisms in a noncoding region of DNA are thought to influence CAD production by controlling the expression of neighboring genes. Polymorphisms in 9p21 have been found to occupy enhancer regions that influence the protein binding of the signal transducer and activator of transcription 1 (STAT1), which regulates the expression of the neighboring CDKN2B gene and CDKN2BAS (also known as ANRIL) within the 9p21 area.

19

The most powerful behavioral risk factor linked to the growth of CAD is smoking. 2 Interactions between genes that control inflammatory pathways and smoking have been discovered in many studies assessing genetic CVD risk. Xie et al. found a significant interaction between the rs20417 SNP in PTGS2, which encodes the cyclooxygenase-2 enzyme, and CAD risk (P for interaction = 0.009) in a case-control study of 900 participants. 21 However, interpretation of this interaction with smoking should be done with caution because the gene has not been independently associated with CVD risk; this would be expected given the high p . The association between APOE polymorphisms and CVD risk tends to be altered by smoking. Major isoforms of apolipoprotein E.22 are encoded by APOE polymorphisms (2, 3, 4).

Humphries et al. found a substantial rise in CAD risk associated with the 4 allele (OR, 2.79; 95 percent CI, 1.59-4.91) in smokers relative to nonsmokers in a study of 2258 males, while 2 carriers and 3/3 carriers did not (P value for association = 0.007). 11 Gustavsson et al. also looked at the relationship between APOE polymorphisms and smoking status in 6269 Swedish people, finding that CAD risk due to smoking was slightly smaller in female 2 carriers (OR, 1.33; 95 percent CI, 0.70-2.52) compared to female carriers of the 3/3 (OR, 1.72; 95 percent CI, 1.29-2.31) or 4 (OR, 3.62; 95 percent CI, 2.32–5.63) alleles (While the interaction was not substantial (P = 0.09), smoking-related CAD risk was trending lower in men carrying the 2 polymorphism compared to the other genotypes. 12 While interesting, further research is needed to establish if the observed relationship is generalizable.

Metabolism of Lipids

Over the last few decades, improvements in diet and lifestyle have resulted in a substantial decrease in serum cholesterol levels in North America and Western Europe, which has been counterbalanced by a rise in emerging regions such as Southeast Asia and the Pacific. 23 GWAS has identified 95 loci that contribute to high-density lipoprotein (HDL), low-density lipoprotein (LDL), or triglyceride metabolism, among other lipid traits. 24 The interaction of genetic and environmental influences on lipid metabolism is still being studied, with the majority of results coming from single research.

Since these dietary components tend to change metabolic and inflammatory pathways, as well as potentially modify CVD risk, there has been a lot of interest in studying gene-diet interactions associated with n-3 and n-6 polyunsaturated fatty acids (PUFAs) (also known as 3 and-6 fatty acids). 25 About 90% of PUFA intake is made up of the n-6 PUFA linolenic acid (LA) and the n-3 PUFA-LA (ALA). 26 Linoleic acid is contained in edible oils and margarines and is metabolized to arachidonic acid; ALA is found in green vegetables, nuts, and certain oils and is metabolized to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (DHA). EPA and DHA can also be used in marine foods. Eicosanoids and docosanoids, which have strong anti-inflammatory effects, are produced by EPA and DHA. 27, 28

PUFAs seem to alter the effects of many genes involved in lipid metabolism, including the FADS gene cluster, which encodes desaturases that metabolize LA and ALA, according to several reports. 24

In a sample of 3575 Europeans, PUFA consumption substantially altered the influence of the FADS1 polymorphism (rs174546), with higher HDL concentrations in rs174546-C carriers who ingested large levels of n-6 PUFAs and no effect on those who consumed low amounts of n-6 PUFAs (P for interaction = 0.02). 28 ABCG1, which encodes the adenosine triphosphate binding cassette transporter G1, which mediates cholesterol transfer from cells to HDL lipoproteins, is another gene that regulates lipid metabolism and is affected by PUFA intake. 29 In a study of 2435 Spanish participants, Abellan et al. looked at the impact of dietary PUFA intake on the interaction between a polymorphism in the ABCG1 gene (rs4148102) and different lipid phenotypes. High PUFA consumption was linked to higher mean total cholesterol (246.8 32.9 vs 198.0 37.5) and LDL concentration (159.0 32.6 vs 114.3 33.1) in homozygous carriers of the rs4148102-A allele, but no major variations were seen with low PUFA consumption (P for correlation = 0.006 and 0.003 for total cholesterol and LDL, respectively). Despite the fact that ABCG1 is predominantly involved in HDL metabolism, there was no clear relationship between ABCG1 polymorphisms and HDL in relation to PUFA intake. 30

Additional behavioral influences have been shown to influence gene-lipid metabolism interactions. In 1123 European participants, Smith et al. looked at the impact of sedentary behavior, as measured by screen viewing time, on the relationship between LIPG polymorphisms (rs2000813 and rs6507931) and HDL concentration. HDL was slightly lower in female homozygous carriers of the rs6507931-T allele compared to C allele carriers in participants reporting high screen viewing times (2.6 h/d; $P = 0.005$), although there was no major genetic impact in participants reporting low screen viewing times (P for association = 0.003).³¹ Higher HDL concentrations have also been found in Chinese individuals that are homozygous for the rs2000813-T allele and drink alcohol, relative to nondrinkers.³²

The effects of genes that control lipid metabolism tend to be altered by smoking. The ABCG5 and ABCG8 genes are responsible for transporting cholesterol from enterocytes to the interstitial lumen.^{33, 34} Polymorphisms in the ABCG5/8 loci have been found to interfere with smoking in Latin Americans. ABCG5 polymorphisms impacted HDL and total cholesterol levels in smoking, while ABCG8 polymorphisms controlled triglyceride and very low density lipoprotein levels. Nonsmokers' lipid levels were unaffected by these polymorphisms. Smoking is thought to reduce HDL by downregulating ABCG5/8 and inhibiting reverse cholesterol transport.

However, further research is required to validate the mechanisms behind this interaction.³⁴ Several gene-environment associations that seem to influence lipid metabolism have been identified, but they have mostly been published in single studies. Replication trials are also needed to provide further definitive proof for these results.

Diabetes and Metabolic Syndrome are two terms that are used interchangeably.

Over the last three decades, the global burden of diabetes has risen sharply.⁵ Since diabetes is linked to both genetic and environmental causes, correlations between the two are likely to play a role in its rising prevalence. However, little research has been conducted to examine how environmental factors influence the impact of genetic polymorphisms linked to diabetes, metabolic syndrome, and insulin resistance.

The Diabetes Prevention Program Research Group found a 58 percent decrease in diabetes risk with a lifestyle-based intervention (consisting of an instructional program promoting food, exercise, and behavior modification) relative to placebo in a randomized controlled study with people at higher risk for developing diabetes. 35 Florez et al. examined whether polymorphisms (rs12255372 and rs7903146) in the TCF7L2 gene impaired diabetes risk and whether this risk could be changed by treatments in 3548 participants with genetic evidence. In the placebo population, homozygous carriers of the rs7903146-T allele were at an elevated genetic risk of contracting diabetes (hazard ratio, 1.81; 95 percent CI, 1.21-2.70; $P = 0.004$), but there was no such risk in the lifestyle intervention community (hazard ratio, 1.15; 95 percent CI, 0.68-1.94; $P = 0.60$). Although the research was not possibly powered to test relationships, formal interaction measurements were nonsignificant. Additional studies have shown that nutritional factors such as whole grain intake and glycemic index change the diabetes risk associated with TCF7L2 polymorphisms. 36 and 37

Diabetes is clearly a polygenic disorder, as evidenced by GWAS, with many loci now known to affect diabetes risk. TCF7L2 (rs12255372), HHEX (rs1111875), CDKAL1 (rs7756992), IGF2BP2 (rs4402960), SLC30A8 (rs13266634), WFS1 (rs10010131), CDKN2A/B (rs564398, rs10811661), PPARG (rs1801282), and KCNJ11 are among 10 genes correlated with diabetes (rs5219). Participants with a high gene score (12) had a higher risk of diabetes while they ate a mostly western diet (OR, 2.06; 95 percent CI, 1.48-2.88 for the highest western diet quartile), while those with a low gene score (10) did not (P for interaction = 0.02), implying that a western diet affects diabetes risk among those genetically predisposed to it. 38

Saturated fats and polyunsaturated fatty acids (PUFAs) have been studied in gene-environment studies after several observational studies suggested that dietary fat intake affects insulin response and diabetes danger. 39, 40, and 41. Phillips et al. looked into how the ACSL1 gene (rs9997745), which encodes long-chain Acyl CoA Synthetase, an essential enzyme for fatty acid metabolism, interacts with dietary fat intake and diabetes danger. 42 and 43 A high saturated fat diet, but not a low saturated fat diet, raised the risk of metabolic syndrome in homozygous carriers of the rs9997745-G allele. Furthermore, the polymorphism raised the risk of metabolic syndrome in people who ate a low-n-3 PUFA diet, but not in people who ate a high-n-3 PUFA diet. 43 Similar to n-3 PUFA to serum fatty acid levels, the metabolic syndrome vulnerability associated with other genes that control inflammatory pathways (such as LTA and TNF-) tends to differ. 14 Ferguson et al. investigated whether serum saturated fatty acid concentrations affected insulin resistance linked to the ADIPOQ (rs266729) gene, which encodes adiponectin, and the ADIPOR1 (rs10920533) and ADIPOR2 (rs10920533) genes, which encode adiponectin receptors (rs6489323). The homeostasis model assessment-insulin resistance index was higher in the high serum saturated fatty acid group compared to the low serum saturated fatty acid group in homozygous carriers of the rs266729-C (ADIPOQ) minor allele; however, this effect was less pronounced in carriers of the G allele (P for interaction = 0.01). In homozygous carriers of the rs10920533-A (ADIPOR1) minor allele, a related effect was observed (P for association = 0.004). Saturated fatty acid accumulation has little effect on ADIPOR2 polymorphisms. 44 While replication experiments are required to validate any of these findings, these findings indicate that saturated fatty acid consumption alters the effects of multiple genes involved in lipid metabolism, inflammation, and insulin regulation.

Obesity is a problem that affects many people.

Obesity has doubled in prevalence over the last 30 years, affecting 9.8% of men and 13.8 percent of women around the world. North America has the highest mean body mass index (BMI). 4 Dietary shifts and a more sedentary lifestyle have created an "obesogenic" climate, with individuals with a higher genetic risk manifesting the obesity phenotype more often. Several behavioral factors can influence the impact of genetic polymorphisms on obesity risk.

Polymorphisms in the FTO gene contribute greatly to hereditary interindividual weight heterogeneity and raise obesity incidence by 1.6 times per risk allele. 46, 45 A strong relationship between polymorphisms in the FTO gene and physical activity has been discovered by meta-analysis. Kilpelainen et al. examined the role of physical exercise in the relationship between FTO polymorphisms (rs9939609 or an SNP in high correlation disequilibrium) and obesity risk in a meta-analysis of 45 studies in adults (218,166 participants) and 9 studies in children (19,268 participants). Based on standardized standards, participants were classified as "active" or "inactive." 15 Each rs9939609-A risk allele was linked to an increased obesity risk of 1.23 (95 percent CI, 1.20-1.26) and a 0.36 rise in BMI in adults. Physical activity decreased the effect of the FTO risk allele on BMI by 30% (P value for interaction = 0.005) and reduced the risk of obesity by 27% (P for interaction = 0.001). In infants, there was no evidence of a gene-physical activity relationship. 15 An adequate sample size may be reached by meta-analysis to assess the impact of the FTO-physical activity relationship on obesity risk with greater confidence, adding to the growing body of evidence that hereditary obesity risk is responsive to physical activity level. While prospective research evaluating physical activity interventions on obesity risk associated with FTO has been inconclusive, identifying this gene-environment association could guide potential behavioral therapies targeting those at elevated genetic risk. 16, 47, and 48. More research is needed to see how this relationship can be used to create interventions that impact health results.

Saturated fat consumption tends to affect the risk of obesity associated with FTO. In separate Caucasian (rs9939609) and Latin American (rs1121980) populations, Corella et al. discovered an important association between increased saturated fat consumption and FTO polymorphisms on BMI. BMI was higher in homozygote carriers of the risk alleles who ate a high-fat diet, but there was no major genetic impact in those who ate a low-saturated-fat diet. 49

Saturated fat consumption has also been found to interfere with APOA2 polymorphisms to affect obesity in people of various ethnic backgrounds. 50 Corella et al. discovered that the APOA2-265T > C polymorphism has a consistent gene-diet relationship in Caucasian and Hispanic populations. The genetic risk of obesity varied greatly depending on saturated fat consumption across populations, with C allele homozygotes eating large levels of saturated fat having a 1.84 (95 percent CI, 1.38-2.47) increased risk of obesity relative to those consuming low amounts of saturated fat having a 0.81 (95 percent CI, 0.59-1.11) increased risk. 17 The findings were also repeated in Asian and Mediterranean cultures, indicating that this relationship is generalizable across ethnic groups. 51

Several studies have looked at the impact of gene-environment interactions in loci controlling inflammatory pathways, as proinflammatory pathways influence obesity growth. Razquin et al. looked at whether a Mediterranean diet (MD) changed the association between IL-6 genetic polymorphisms (-174G > C) and weight gain over a 3-year cycle in a prospective trial. Patients were assigned to one of three groups: a low-fat diet (control), a Mediterranean diet with virgin olive oil, or a Mediterranean diet with nuts. Weight gain was slightly different in -174-CC carriers on an MD and virgin olive oil diet relative to the control diet (P for association = 0.028).⁵² Similarly, Jourdan et al. discovered that the genetic likelihood of obesity associated with many genes encoding inflammatory cytokines, such as IL-6 and IL-2, varied depending on the amount of PUFA in the membrane.⁵³ These findings shed light on the inflammatory pathways that can be influenced by dietary conditions in order to change hereditary obesity risk. However, unlike the robust gene-environment interactions associated with FTO and APOA2, dietary interactions with genes controlling inflammatory pathways have mostly been observed in single populations, and further replication is needed to validate these results.

Hypertension

Small changes in blood pressure will lead to significant decreases in cardiovascular events in the population, highlighting the importance of individual and population-based interventions to improve blood pressure regulation. Mean systolic blood pressure has been declining in many high-income regions as a result of successful medical therapies and lifestyle improvements, but it has been rising in low-and middle-income regions, such as Africa and Asia, in line with overall CVD patterns.⁵⁴

Few studies have looked at gene-environment associations with blood pressure, and further research is required to confirm these findings, especially in different ethnic groups, so that their generalizability can be better determined. Pan et al. discovered an important link between alcohol intake and hypertension risk in 1575 Chinese people, which was linked to a polymorphism (-344T > C) in the CYP11B2 gene. Hypertension risk was slightly higher in TT (OR, 2.9; 95 percent CI, 1.4-5.7) and TC (OR, 3.0; 95 percent CI, 1.5-5.7) allele carriers compared to the CC genotype (OR, 1.2; 95 percent CI, 0.5-3.0) allele carriers of those who consumed less than 200 g/d of alcohol (P value for association = 0.048).⁵⁵

Surprisingly, some research shows that occupational and community exposures can alter blood pressure genetic control. Menni et al. found that presumed work regulation changed the relationship between a polymorphism (rs11210278) in the EDN2 gene, which encodes endothelin 2, and ambulatory systolic blood pressure in 924 European participants. 56 For the EDN1 gene, homozygous carriers of the rs5369-G allele who indicated work strain had slightly higher systolic blood pressure than heterozygous allele carriers, with no variations found in those who recorded no job strain. 57 Chronic noise sensitivity can help to reduce the risk of hypertension linked to ACE insertion/deletion (I/D) and the ACE G2350A polymorphism. In a single sample of 385 South Asian males, ACE-DD carriers exposed to noise had a 4.49 (95 percent confidence interval, 1.55-12.99) elevated risk of hypertension, while ACE-ID and ACE-II carriers had chances of experiencing hypertension of 2.84 (95 percent confidence interval, 1.3-6.11) and 2.95 (95 percent confidence interval, 0.59-14.65) respectively. As it came to the ACE G2350A polymorphism, GG and GA carriers (OR, 3.97; 95 percent CI, 1.63-9.68) who were regularly prone to loud noise had a higher chance of hypertension than AA carriers (OR, 3.71; 95 percent CI, 1.41-9.76). (OR, 1.20; 95 percent CI, 0.33-4.36). Formal interaction experiments, on the other hand, were not published, and further research is required to provide more conclusive findings. 58

Current Gene-Environment Challenges and Future Directions Cardiovascular Studies

Based on the gene-environment associations that have been discovered so far, it appears that behavior and lifestyle play a significant role in changing the genetic likelihood of developing CVD. The interaction of environmental and genetic factors is complicated, and several key steps are needed to further clarify this area. The lack of replicated research, the need for significant sample sizes, enhancing the accuracy of calculating environmental conditions, and determining clinical impact are all major obstacles in the study of gene-environment interactions in cardiometabolic diseases. ten to fifty To understand the mechanisms of gene-environment interactions found at the population level, translational research is also needed.

Several gene-environment associations have been shown to affect cardiovascular risk, but the mechanisms underlying these effects are still unclear. Environmental factors can alter risk by influencing downstream metabolic pathways or by epigenetic or transcriptional mechanisms that regulate gene expression, but further research is required to validate these hypotheses. 59, 50 Understanding the mechanisms by which these relationships change risk is critical for a better understanding of CVD production and the development of innovative CVD preventive strategies.

The lack of published replicated research for most observed gene-environment interactions is a major methodological issue in this area. As a consequence, there's a chance of publishing bias, which may lead to an overabundance of favorable outcomes in the latest literature. In the future, replication should be a higher priority in gene-environment interaction science, either by testing several, separate populations within the original study or in subsequent studies. Furthermore, several associations have been established in single ethnic groups, but their effect on other ethnic groups remains uncertain. The impact of genetics on a variety of traits has been found to differ depending on race. It's also possible that gene-environment associations differ between ethnic groups, highlighting the importance of studying these influences in different ethnic groups. 60, 61 One barrier to reproduction is that human genetic polymorphisms have comparatively limited consequences in complex disorders, necessitating massive sampling populations to classify genetic effects, research associations, and reproduce results. Meta-analysis is a useful method for getting around this constraint. This was shown successfully with research examining the effects of the FTO-physical activity interaction on obesity risk, in which inconclusive outcomes were found through individual studies, but meta-analysis of results offered a sufficient sample size to identify a meaningful effect, further supporting the generalizability of this interaction. 15

The heterogeneity found in assessing environmental exposures between studies is another methodological weakness in gene-environment science. While certain factors (such as nutritional, physical activity, and psychosocial factors) are simple to quantify, others (such as dietary, physical activity, and psychosocial factors) are more complex. A study's prejudice may be caused by incorrect characterization of environmental exposures. Furthermore, using various measurement instruments will lead to inconsistent outcomes across experiments, limiting the opportunity to repeat findings. This possible cause of error can be reduced by using consistent methods of characterizing environmental variables. Consistent concepts were used to describe both continuous and dichotomous physical activity measurements in the meta-analysis of FTO-physical activity relationship findings, for example, to include a more uniform characterization of the environmental exposure for analysis. 15 Several validated food frequency questionnaires exist to quantify components of food consumption (such as fat intake and vegetable intake) in gene-environment cardiovascular research, and recommendations for using these instruments in gene-environment cardiovascular research may be helpful to provide a more reliable characterization of these environmental factors through studies.

The biggest question in this area is whether these new discoveries can lead to techniques that change personal behavior or clinical practice. Given the field's brief history, it is also unclear if treating genetically vulnerable people would have a therapeutic benefit over current population-based health promotion policies. In theory, this tailored approach to management may have additional benefits, since "at risk" individuals could be more likely to improve their behavior and may benefit more from interventions as a result of their higher baseline vulnerability than the general population. However, it's unknown if such an advantage would be seen in primary preventive communities with a higher genetic risk of CVD, which is a key field for future study. Researchers also found that telling participants of their genetic vulnerability has only a minor impact on their conduct. Awareness of genetic evidence influenced dietary behavior favorably in a meta-analysis of 14 findings, but there were no benefits of smoking or physical activity; and the studies involved were modest in scale and of low quality. 62, 165-191 As a result, more research is required before any therapeutic implementation to see whether behavioral approaches based on gene-environment interaction information will increase clinical outcomes, preferably in the context of prospective studies or randomized controlled trials.

Final Thoughts

Important progress has been made in identifying gene-environment associations that affect CVD, lipid traits, obesity, diabetes, and hypertension in a comparatively short period of time. These associations tend to alter genetic risk, which may contribute to a deeper understanding of the genetic mechanisms that affect CVD progression in the future. Additional study is needed to validate initial comparisons, establish the biological mechanisms by which environmental factors modify genetic risk, and explore techniques that use this information to impact clinical outcomes in order to advance the field.

References

1. Abdelhamid, H. N., M. Dowaidar, M. Hällbrink, and Ü. Langel. 2019. Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform. SSRN Electron. J. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3435895.
2. Abdelhamid, Hani Nasser, Moataz Dowaidar, Mattias Hällbrink, and Ülo Langel. 2020. Gene Delivery Using Cell Penetrating Peptides-Zeolitic Imidazolate Frameworks. *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 300 (June): 110173. <https://doi.org/10.1016/j.micromeso.2020.110173>.
3. Abdelhamid, Hani Nasser, Moataz Dowaidar, and Ülo Langel. 2020. Carbonized Chitosan Encapsulated Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles for Gene Delivery. *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 302 (August): 110200. <https://doi.org/10.1016/j.micromeso.2020.110200>.
4. Ahmad, Almeman, Khalaf Hassan, Rasool Semaab, Moataz Dowaidar, and Al Orainy Mohammad. 2013. The Impact of CYP2C19 Polymorphism on Platelet Reactivity for Guiding Clopidogrel Treatment and Cost Analysis. *Journal of the Saudi Heart Association* 25 (2): 107. <https://doi.org/10.1016/j.jsha.2013.03.005>.
5. Algahsham, Abdullah, Ahmad A. A. Settin, Ahmad Ali, and Hisham Ismail. n.d. Association of MTHFR C677T and A1298C Polymorphisms with Hypertension among Saudi Subjects from Qassim Region. *International Journal of Health Sciences* 6 (1). Accessed June 18, 2021. <http://ijhs.org.sa/index.php/journal/article/view/312>.
6. Algasham, Abdullah, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2011. Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim Region. *International Journal of Health Sciences* 5 (2 Suppl 1): 3–4. <https://www.ncbi.nlm.nih.gov/pubmed/23284552>.
7. Alghasham, Abdullah, Ahmad Ali, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2012. CYP2J2 -50 G/T and ADRB2 G46A Gene Polymorphisms in Saudi Subjects with Hypertension. *Genetic Testing and Molecular Biomarkers* 16 (9): 1027–31. <https://doi.org/10.1089/gtmb.2012.0006>.
8. Alghasham, Abdullah, Ahmad A. Settin, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012a. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
9. Moataz Dowaidar. 2012b. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
10. Ali, Ahmad, Abdullah Alghasham, Hisham Ismail, Moataz Dowaidar, and Ahmad Settin. 2013. ACE I/D and eNOS E298D Gene Polymorphisms in Saudi Subjects with Hypertension. *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS* 14 (4): 348–53. <https://doi.org/10.1177/1470320312459976>.
11. Ali, Ahmed A. A., Nahla M. Wassim, Moataz M. Dowaidar, and Ahmed E. Yaseen. 2013. Genetic Polymorphism of CYP2D6 Gene among Egyptian Hypertensive Cases. *The Journal of Basic & Applied Zoology* 66 (4): 228–33. <https://doi.org/10.1016/j.jobaz.2012.12.002>.
12. Ali, Ahmed A. A., Nahla M. Wassim, Moataz Dowaidar, and Ahmed E. Yaseen. 2013b. Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
13. Moataz Dowaidar. 2013. Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
14. Aljarallah, Badr, Ahmed Ali, Moataz Dowaidar, and Ahmad Settin. 2011. Prevalence of α -1-Antitrypsin Gene Mutations in Saudi Arabia. *Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association* 17 (4): 256–60. <https://doi.org/10.4103/1319-3767.82580>.
15. Dowaidar, M., J. Regberg, D. A. Dobchev, and T. Lehto. 2017. Refinement of a Quantitative Structure–activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. *International Journal of*. <https://link.springer.com/content/pdf/10.1007/s10989-016-9542-8.pdf>.

16. Dowaidar, Moataz. 2017. In-Silico Design of Peptide-Based Transfection Systems, in-Vitro Validation, and up-Take Pathways Investigation. Department of Neurochemistry, Stockholm University.
17. Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis. Department of Biochemistry and Biophysics, Stockholm University. <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1242000>.
18. Moataz Dowaidar. Cardiometabolic Conditions Could Be Related to Vitamin D Deficiency. The Genetic Determinants That Affect Vitamin D Pathways May Be Solved with Nanomedicines. <https://doi.org/10.31219/osf.io/nqewr>.
19. Moataz Dowaidar. Different Insulin Resistance and Inflammation Pathways Are Influenced by Genetic Factors in Metabolic Syndrome. Gene Therapy Enables Early Recognition and Treatment of the Genetic Factors. <https://doi.org/10.31219/osf.io/gqwj2>.
20. Moataz Dowaidar. Gene Therapy Has Been Shown to Be Valuable for Understanding Complex Disease Pathophysiologies. The Medical Profession as a Whole Will Have to Invest in Specialized Investigations. <https://doi.org/10.31219/osf.io/8fg9y>.
21. Moataz Dowaidar. Genetic and Epigenetic Discoveries Hold Promising Avenues in Cardiovascular Prevention and Management (CVDs). Key Nucleic Acids Are Being Researched and Developed for Medicinal Use. <https://doi.org/10.31219/osf.io/hk7pe>.
22. Moataz Dowaidar. Genome Editing Can Now Be Carried out in an Isogenic Setting. It Can Be Effectively Transmitted to Somatic Tissues in Mice, but Not to Humans. Despite These Doubts, CRIS Has Great Potential as a Medical Promise. <https://doi.org/10.31219/osf.io/4rn3v>.
23. Moataz Dowaidar. Genome-Wide Association Experiments Have Uncovered a Slew of Cardiometabolic Trait-Associated Variants. This Information Can Be Useful in the Implementation of New Diagnostic and Treatment Strategies. <https://doi.org/10.31219/osf.io/4vws8>.
24. Moataz Dowaidar. Genome-Wide Association Studies (GWAS) Have Revolutionized Our View of Human Health and Disease Genetics and Offered Novel Gene Therapy Targets. <https://doi.org/10.31219/osf.io/rvm3z>.
25. Moataz Dowaidar. Metabolic Syndrome_ the Presence of Inflammatory Mechanisms in Abdominal Obesity Is Undeniable, Gene Therapy Using Nanoparticles and Adenoviruses Technologies Is Promising. <https://doi.org/10.31219/osf.io/2j5xt>.
26. Moataz Dowaidar. miRNAs May Be Used as Preventive Agents for Metabolic Diseases in the near Future. Understanding the Interplay between pro-Adipogenic_ and Anti-Ad Pipogenic miRNA' Could Lead to New Biomarkers. <https://doi.org/10.31219/osf.io/3dr8c>.
27. Moataz Dowaidar. Nanomedicine Has Elegantly Attempted to Cure Multiple Gene Polymorphisms and Mutations in Cardiovascular Diseases Using Gene Therapy Techniques. <https://doi.org/10.31219/osf.io/d3x8g>.
28. Moataz Dowaidar. Thrombosis Pathways and Therapeutic Strategies. <https://doi.org/10.31219/osf.io/57vyz>.
29. Moataz Dowaidar. What Genomic Research Has Told Us about the Obesity and Its Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ym49s>.
30. Moataz Dowaidar. Exosomes Can Make the Use of Circulating miRNA as a Biomarker More Feasible. The Aim of Gene Therapy Should Be to Learn Everything There Is to Know about miRNA Activity. <https://doi.org/10.31219/osf.io/edkua>.
31. Moataz Dowaidar. Anti-Sense Pathways Have Been Generated Using siRNA. The Liver and Other Often Used Organs Will Now Be Targeted. <https://doi.org/10.31219/osf.io/m6xvp>.
32. Moataz Dowaidar. CrisPR/CRIS Systems Are Highly Effective and Useful for Genomic Manipulation. Despite This, Cardiac Treatment Remains Difficult due to Existing Genome Editing and Delivery Processes. <https://doi.org/10.31219/osf.io/3nwzd>.
33. Moataz Dowaidar. Discoveries in Gene-Environment Interactions That Influence CVD, Lipid Traits, Obesity, Diabetes, and Hypertension Appear to Be Able to Influence Gene Therapy. <https://doi.org/10.31219/osf.io/cr5af>.
34. Moataz Dowaidar. Genome Editing's Potential Target Diseases in the Cardiovascular Field. <https://doi.org/10.31219/osf.io/gc23p>.

35. Moataz Dowaidar. Key Genetic Factors in the Metabolic Syndrome Predisposition Which May Be a Therapeutic Options by Gene Therapy. <https://doi.org/10.31219/osf.io/f38sk>.
36. Moataz Dowaidar. miRNA Can Be a Part of Both the Onset and Cure of Coronary Heart Disease. <https://doi.org/10.31219/osf.io/teqh8>.
37. Moataz Dowaidar. Preclinical Studies and Clinical Trials Have Sparked Interest in Certain Biological Medications for Atherosclerotic Coronary Heart Disease. <https://doi.org/10.31219/osf.io/ts8mh>.
38. Moataz Dowaidar. Researchers Would Be Able to Develop a Detailed Picture of Chromatin in Disease, Which Would Be Useful for Gene Therapy. <https://doi.org/10.31219/osf.io/m9z48>.
39. Moataz Dowaidar. The Cardiometabolic-Based Chronic Disease Model Lays the Foundations for Accurate, Evidence-Based Preventive Targeting and Gene Therapy. <https://doi.org/10.31219/osf.io/up9z4>.
40. Moataz Dowaidar. 2D MOFs Have Unique Features for Biological Applications. They Can Be Utilized for Gene Therapy, Bioimaging, Biosensing, Photodynamic Therapy, and Tissue Engineering. <https://doi.org/10.31219/osf.io/4q9ct>.
41. Moataz Dowaidar. 3D Bioprinting for Enhanced Vascularization, and Gene Editing to Provide a More Favorable Immunological Response Are Just Some of the Potential Uses of Carbon Materials. <https://doi.org/10.31219/osf.io/v2xy8>.
42. Moataz Dowaidar. Anderson–Fabry Disease Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/tcgka>.
43. Moataz Dowaidar. Antisense Oligonucleotides (ASOs) and CRISPR Systems Are Promising Gene Therapy Treatments for Alzheimer’s Disease. <https://doi.org/10.31219/osf.io/ws796>.
44. Moataz Dowaidar. Any Alteration in PPAR Genomic Sequence, Splicing Pattern, or PTM Is Likely to Cause Major Alterations in Its Function. In Personalized Medicine, Such Data Becomes More Significant in Gene Therapy Design. <https://doi.org/10.31219/osf.io/y8n79>.
45. Moataz Dowaidar. Applying Genome-Wide Association Technology to Brain Diseases Enables the Discovery of lncRNAs Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hm4eu>.
46. Moataz Dowaidar. Autophagy and Proteostasis Adjustment Role in Normal Brain Function and Neurodegenerative Disorders. <https://doi.org/10.31219/osf.io/m4yra>.
47. Moataz Dowaidar. Basal Ganglia-Cerebellar and Brainstem-Cerebellar Circuits May Interact Improperly with Dystonia. Linking Network Disruptions to Cell Failure Will Enable Understanding Pathophysiology and Designing Gene Therapy Methods. <https://doi.org/10.31219/osf.io/8w35s>.
48. Moataz Dowaidar. Blood Products Are Used to Treat a Multitude of Diseases, so the Blood Transfusion System Needs to Be Enhanced. CRISPR/Cas9 Has Made It Viable to Make HLA Class I-Deleted Blood Products to Avoid Rejection. <https://doi.org/10.31219/osf.io/egr3n>.
49. Moataz Dowaidar. Calixarenes (CAs) Are Promising in Biomedicine, Biosensing, Bioimaging and Gene Delivery Systems. <https://doi.org/10.31219/osf.io/n9vjy>.
50. Moataz Dowaidar. CAR T Cell Research Has Quickly Advanced from the Bench to the Clinic and Back. The Results of the Trials Have Revealed New Mechanisms. <https://doi.org/10.31219/osf.io/f9wm7>.
51. Moataz Dowaidar. CAR T-Cell Treatment Remains Clinically Challenging. Therapeutic Strategies May Be Designed to Cut off Immunotherapy Utilizing Safety Switches. <https://doi.org/10.31219/osf.io/s7x4y>.
52. Moataz Dowaidar. Central Nervous System Gene Therapy Has Entered a New Development Paradigm. New Techniques Are Being Employed for a Wide Range of Illness Indications and Pathways. <https://doi.org/10.31219/osf.io/j49wz>.
53. Moataz Dowaidar. Chronic Obstructive Pulmonary Condition (COPD) Is a Prevalent, Preventable, and Curable Illness with Persistent Respiratory Symptoms and Airflow Limitation. <https://doi.org/10.31219/osf.io/vkdut>.
54. Moataz Dowaidar. CircRNAs Have the Potential to Aid in the Diagnosis and Treatment of Lipid Diseases. <https://doi.org/10.31219/osf.io/y3hp4>.
55. Moataz Dowaidar. Clinical Symptoms, Underlying Pathogenesis, and the Prospect of Tailored Therapies Have All Benefited from Genetic Discoveries in Parkinson’s Disease. <https://doi.org/10.31219/osf.io/pdzqb>.
56. Moataz Dowaidar. Code Distribution of siRNA for Cancer Genes such as p53 and Bcl2 Family Genes Has Demonstrated Efficacy in Killing Cancer Cells. Nanoparticles Can Produce a Surface Where Numerous Drugs May Be Coupled, Allowing Combinatory Treatment. <https://doi.org/10.31219/osf.io/hvcese>.

57. Moataz Dowaidar. Cognitive Deficiencies Pathophysiology Are Mainly an Unknown Area. Curing the Neurological Conditions Could Be an Objective for Gene Therapy. <https://doi.org/10.31219/osf.io/23xf8>.
58. Moataz Dowaidar. CRISPR-Based Gene Editing Is Presently Being Tried in Many Clinical Trials. <https://doi.org/10.31219/osf.io/qbngx>.
59. Moataz Dowaidar. CRISPR–Cas9 Gene Editing as a Tool for Developing Immunotherapy for Cancer. <https://doi.org/10.31219/osf.io/dvr4t>.
60. Moataz Dowaidar. CRISPR/Cas System Research Has Advanced Significantly in Biological sciences. There Are Still Many Challenges to Effective Delivery before Efficient Gene Editing May Be Achieved. <https://doi.org/10.31219/osf.io/mc26v>.
61. Moataz Dowaidar. CRISPR/Cas9 Genome Editing Technology Applications in Biological and Biomedical Fields. <https://doi.org/10.31219/osf.io/ctqbe>.
62. Moataz Dowaidar. Critical Limb Ischemia Potential Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/aqcpt>.
63. Moataz Dowaidar. Deep Learning Algorithms for scRNAseq Analysis Have Yielded Positive Results, but There Are Still More Promising Ways That Need to Be Developed for Regenerative Medicine. <https://doi.org/10.31219/osf.io/dh2pt>.
64. Moataz Dowaidar. Depression May Be Epigenetically Controlled by miRNAs Making It a Diagnostic or Gene Therapy Target. <https://doi.org/10.31219/osf.io/fw65m>.
65. Moataz Dowaidar. Dermatophytes: Role of Host Genetics in the Development of Illness. <https://doi.org/10.31219/osf.io/mf3bu>.
66. Moataz Dowaidar. Developments in Biomedical Technology Will Increase the Importance of mRNA in Treating Brain Tumors, as Well as Other Malignancies. <https://doi.org/10.31219/osf.io/tvj5x>.
67. Moataz Dowaidar. Downstream Processing of Virus, Virus-like Particles and Nanoparticulate Inclusion Bodies to Be Used as Gene Delivery Vehicles for Human Gene Therapy Applications. <https://doi.org/10.31219/osf.io/exa3q>.
68. Moataz Dowaidar. Dravet Syndrome Is a Severe Developmental and Epileptic Encephalopathy. Fenfluramine and Gene Therapy Are Promising. <https://doi.org/10.31219/osf.io/zvq8y>.
69. Moataz Dowaidar. Exosomes' Function in Cardiovascular Protection and Neovascularization Implies That They Might Be Used to Treat Ischemia and Atherosclerotic Cardiovascular Diseases. <https://doi.org/10.31219/osf.io/2h8c7>.
70. Moataz Dowaidar. Ferropsis Cell Death Can Cause Complications That May Be Difficult to Detect and Quantify: Autophagy Role and Possible Therapeutics. <https://doi.org/10.31219/osf.io/zd2jg>.
71. Moataz Dowaidar. Following the Discovery of Anti-MDA5 Ab, the Clinical Understanding of Dermatomyositis Has Been Improved. <https://doi.org/10.31219/osf.io/j2t5f>.
72. Moataz Dowaidar. For the Treatment of Cystic Fibrosis, RNA Medicines, Gene Transfer Therapies, and Gene Editing Treatments Have Potential. <https://doi.org/10.31219/osf.io/6afzm>.
73. Moataz Dowaidar. Frontotemporal Dementia Is a Complex Disorder with a Wide Spectrum of Clinical Symptoms. Personalized Medicine and Gene Therapy Are Promising Strategies for Treatment. <https://doi.org/10.31219/osf.io/gh4x7>.
74. Moataz Dowaidar. G6PD Deficiency Is a Common Genetic Trait That Can Protect Heterozygotes from Dying from Malaria. <https://doi.org/10.31219/osf.io/g2kza>.
75. Moataz Dowaidar. Gastric Cancer Is the World's Second-Largest Death Cause. Peptides Can Be Used to Deliver Radiation or Other Fatal Chemicals to Tumors. <https://doi.org/10.31219/osf.io/eu5mj>.
76. Moataz Dowaidar. Gene Doping May Be Possible for Lifestyle Enhancement. <https://doi.org/10.31219/osf.io/8xkm5>.
77. Moataz Dowaidar. Gene Expression Assays Gather Evidence That They Can Provide Useful Therapeutic Information in Young Women. <https://doi.org/10.31219/osf.io/d372s>.
78. Moataz Dowaidar. Gene Therapy and Genome-Editing Treatments That Can Protect Patients from Coronary Artery Disease Are under Investigation. <https://doi.org/10.31219/osf.io/xqgf8>.
79. Moataz Dowaidar. Gene Therapy Approaches for Hemophilia A and B. <https://doi.org/10.31219/osf.io/ufc4g>.

80. Moataz Dowaidar. Gene Therapy for the Central Nervous System Has Been Initiated. This Expansion Will Require Some Degree of Simplicity in Delivery Processes. <https://doi.org/10.31219/osf.io/hdy5q>.
81. Moataz Dowaidar. Gene Therapy for the Treatment of Spinal Muscular Atrophy. <https://doi.org/10.31219/osf.io/kpz5f>.
82. Moataz Dowaidar. Gene Therapy May Benefit Inherited Ichthyoses with Concurrent Fungal Infections and Severe Ich Thyroidoses. <https://doi.org/10.31219/osf.io/zxmun>.
83. Moataz Dowaidar. Gene Therapy May Target APOE for Alzheimer's Disease. <https://doi.org/10.31219/osf.io/3y52k>.
84. Moataz Dowaidar. Gene Therapy Promises Accurate, Targeted Administration and Overcoming Drug Resistance in Diverse Cancer Cells. <https://doi.org/10.31219/osf.io/j34n6>.
85. Moataz Dowaidar. Gene Therapy Targeting FVIII, FIX for Haemophilia Treatment. <https://doi.org/10.31219/osf.io/qcbwp>.
86. Moataz Dowaidar. Gene Therapy Targeting PRMT5 May Be Useful in Immunotherapy. <https://doi.org/10.31219/osf.io/gkw8j>.
87. Moataz Dowaidar. Gene Therapy Using Extracellular Vesicles Loaded with miRNA Derived from Bone Marrow Mesenchymal Stem Cells Is a Cell-Free Medication Delivery Method Used in a Variety of Diseases. <https://doi.org/10.31219/osf.io/3znvw>.
88. Moataz Dowaidar. Genetic Engineered MSCs Are Attractive Possibilities for Regenerative Stem-Cell Therapy to Treat Several Liver Diseases. <https://doi.org/10.31219/osf.io/4cfrd>.
89. Moataz Dowaidar. Genetic Variants Shared between Alzheimer's Disease and Parkinson's Disease Have Been Discovered in Blood and Brain Samples. Somatic Mosaicism Might Function as an Accelerator. <https://doi.org/10.31219/osf.io/tr58n>.
90. Moataz Dowaidar. Genome-Wide Association Studies Promise to Discover Novel Indicators of Hypertension. Endothelin-Related SNPs Are Currently in Clinical Trials. <https://doi.org/10.31219/osf.io/2n4wa>.
91. Moataz Dowaidar. Gingival and Intraventricular Haemorrhages Are Severe Newborn Diseases Causing Damage to White Matter and Neurological Dysfunction in Surviving Newborns Who Can Benefit from Gene Therapy. <https://doi.org/10.31219/osf.io/qb84p>.
92. Moataz Dowaidar. Glioblastoma Therapeutic Approaches Were Established Utilizing Contemporary Discoveries in Delivering Medicines to the Brain as Smart Nanoparticles for Focused Therapy. <https://doi.org/10.31219/osf.io/db4f6>.
93. Moataz Dowaidar. Haemophilia Gene Therapy Is in Clinical Studies, Making Continuous Safety and Efficacy Testing a Key Emphasis. <https://doi.org/10.31219/osf.io/sa8ny>.
94. Moataz Dowaidar. Hematopoietic Stem Cell Transplantation and Gene Therapy Are the Sole Treatments for Sickle Cell Disease and Other Hemoglobinopathies. <https://doi.org/10.31219/osf.io/v8xqc>.
95. Moataz Dowaidar. Huntington's Disease Gene Therapy and Nanomedicines May Be Available Shortly. <https://doi.org/10.31219/osf.io/rxvgd>.
96. Moataz Dowaidar. Hybrid Gene Therapy Designed to Fully Understand the Underlying Molecular Cancer Process May Be a Feasible Option. <https://doi.org/10.31219/osf.io/ajyfd>.
97. Moataz Dowaidar. Hydrogels Are Promising Considering Their Incredible Capacity to Modify, Encapsulate and Co-Deliver Medicinal Compounds, Cells, Biomolecules, and Nanomaterials. <https://doi.org/10.31219/osf.io/px3qy>.
98. Moataz Dowaidar. Immune Evasion Is Linked to Histone Variation Malfunction. Gene Therapy Could Provide Tools for Targeting Histone Variant Deposition as a Critical Part of Its Pharmacology. <https://doi.org/10.31219/osf.io/kjm76>.
99. Moataz Dowaidar. Implementing the Human Artificial Chromosome Gene Therapy Platform Remains Challenging, but Continuous Animal Model Research Will Advance the Platform Closer to Clinical Trials. <https://doi.org/10.31219/osf.io/a53f7>.
100. Moataz Dowaidar. Inflammatory Breast Cancer Remains the Most Aggressive Form of Breast Cancer. A Multimodality Therapeutic Plan Has Shown Improved Survival Results. <https://doi.org/10.31219/osf.io/cr935>.

101. Moataz Dowaidar. Inherited Immunohematological and Metabolic Diseases Have the Potential to Improve Significantly, or Be Cured, Using Haematopoietic Stem Cell Transplantation Gene Therapy. <https://doi.org/10.31219/osf.io/ukbnm>.
102. Moataz Dowaidar. Insulin and IGF-1 Receptors Mutations Can Lead to Targets for Gene Therapy in Diabetes, Obesity, and Metabolic Syndrome. <https://doi.org/10.31219/osf.io/s86x5>.
103. Moataz Dowaidar. Integrating High-Throughput Genetics and Neuroimaging Technologies Promises Greater Information on Neurobiological Anomalies in Neurodegenerative Diseases. <https://doi.org/10.31219/osf.io/hpgyz>.
104. Moataz Dowaidar. Intravitreal and Subretinal Injections Currently Deliver Most Gene Therapy, Including siRNA for Eye Illnesses. Non-Viral Vectors May Provide Targeting. <https://doi.org/10.31219/osf.io/rjkhy>.
105. Moataz Dowaidar. LncRNA Regulating Reprogramming Glucose Metabolism Has Become One of the Most Tempting Antineoplastic Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hqma5>.
106. Moataz Dowaidar. lncRNAs Are Upregulated and Downregulated in OS Cells. Angiogenesis, Metastasis, Cell Signaling, Autophagy, and Death Are among Biological Processes That RNAs Play a Role in. <https://doi.org/10.31219/osf.io/48n7q>.
107. Moataz Dowaidar. Magnetic Nanoparticles Are Widely Used in Drug Delivery, Imaging, Diagnosis, and Targeting. It Has Promises for the Treatment of Inflammatory Disorders such as Rheumatoid Arthritis. <https://doi.org/10.31219/osf.io/p2gme>.
108. Moataz Dowaidar. Many miRNAs Participate in Inflammatory Regulation and Bone Metabolism. Overexpression of miR21 and miR155 Releases Proinflammatory Cytokines. <https://doi.org/10.31219/osf.io/2wuvp>.
109. Moataz Dowaidar. MiR490's Diagnostic Capacity Was Demonstrated in Various Cancer Kinds and Diseases, Adding to Its Clinical Value. <https://doi.org/10.31219/osf.io/wysre>.
110. Moataz Dowaidar. miRNAs Have an Impact on Xeno-Infectious Diseases by Influencing Host And/or Infection Factors. <https://doi.org/10.31219/osf.io/7qewx>.
111. Moataz Dowaidar. Mutations in MED12 Lead to Mental Retardation, Including Opitz–Kaveggia Syndrome, Ohdo Syndrome, Lujan–Fryns Syndrome, and Psychosis. It's a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/cyns8>.
112. Moataz Dowaidar. Nanocarriers Can Be Used to Control the Activity of Genome Editing in a Spatiotemporal Way by Using Stimulusresponsive Nanocarriers. <https://doi.org/10.31219/osf.io/nua89>.
113. Moataz Dowaidar. Nanomaterials Were Formed into Various Shapes, with Functionalization Aimed at Various Internalization Processes. Their Nanoscale Size Allows Drugs to Reach Cells or Extracellular Environments. <https://doi.org/10.31219/osf.io/p2ajv>.
114. Moataz Dowaidar. Nanomedicine Is Offering Promising Strategies for Tumor Blockade Treatment. <https://doi.org/10.31219/osf.io/yzxuq>.
115. Moataz Dowaidar. Network Medicine Might Lead to New Treatments for Dyslipidemia. It Will Be a Challenging Method to Implement in a Clinical Context. <https://doi.org/10.31219/osf.io/nksbw>.
116. Moataz Dowaidar. Neuroinflammation Caused by Activated Microglia and Astrocytes Can Contribute to the Progression of Pathogenic Damage to Substantia Nigra Neurons, Playing a Role in Parkinson's Disease Progression. <https://doi.org/10.31219/osf.io/ac896>.
117. Moataz Dowaidar. Neurologists Rarely Perform Genetic Testing for Parkinson's Disease. Evidence Suggests That Many Patients with Major Genetic Variants Go Undiagnosed. <https://doi.org/10.31219/osf.io/ykpb2>.
118. Moataz Dowaidar. Neuronal Intranuclear Hyaline Inclusion Disease Is a Neurodegenerative Condition Which Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/upgqd>.
119. Moataz Dowaidar. New Therapies Aim at Restoring the Molecular, Morphological, and Functional Integrity of Parkinson's Specific Brain Circuits. <https://doi.org/10.31219/osf.io/dvyxc>.
120. Moataz Dowaidar. Not All lncMIRHG's Are 'Junk Transcripts,'. lncMIRHG Loci May Make Both Functional miRNAs and lncRNAs, Which Can Work Together or Separately. <https://doi.org/10.31219/osf.io/a567w>.
121. Moataz Dowaidar. Nrf2 Signaling Pathways Are Part of a Wider Network of Signaling Pathways Regulating Thymoquinone Therapeutic Actions Which Need Innovative Formulations and Delivery Methods. <https://doi.org/10.31219/osf.io/u2fa7>.

122. Moataz Dowaidar. Omics Should Be Integrated with Genomics to Uncover Molecular Networks and Tissue and Single-Cell Epigenetic Changes. With These Findings, Targeted Pseudoexfoliation Syndrome and Glaucoma Gene Therapy Procedures May Be Viable. <https://doi.org/10.31219/osf.io/48fj5>.
123. Moataz Dowaidar. Ophthalmic Gene and Cell Therapies. <https://doi.org/10.31219/osf.io/n84m9>.
124. Moataz Dowaidar. P21 Is a Flexible, Multi-Functional Protein. It Governs Various Tumor Cell Activities, Including Autophagy. p21 Is a Possible Radiotherapy Target. <https://doi.org/10.31219/osf.io/ydkca>.
125. Moataz Dowaidar. Parkinson's Disease Simulating Complexity via Improving the Identification of Significant Genetic Alterations and Environmental Contaminants Should Be a Priority. <https://doi.org/10.31219/osf.io/pmcu9>.
126. Moataz Dowaidar. Patient-Specific Microphysiology Systems Are Likely to Become a Crucial Aspect of Translational Research and Precision Medicine. <https://doi.org/10.31219/osf.io/bc8fr>.
127. Moataz Dowaidar. Patients with PMD Who Are Thoroughly Screened by Genomic Medicine Have a Considerable Chance of Benefiting Greatly from Whole-Genome Sequencing. <https://doi.org/10.31219/osf.io/dajft>.
128. Moataz Dowaidar. Polydopamine Nanoparticles' Activity and Long-Term Stability Should Be Fully Studied for Gene Therapy Applications. <https://doi.org/10.31219/osf.io/x4nej>.
129. Moataz Dowaidar. Potential Therapeutics for Primary Mitochondrial Disorders. <https://doi.org/10.31219/osf.io/6pz5k>.
130. Moataz Dowaidar. Potentials of Medicinal Nanostructured Diamond Particles and Coatings. <https://doi.org/10.31219/osf.io/h68xz>.
131. Moataz Dowaidar. Preclinical Investigations Revealed Possibilities for Salmonella Tumor Treatment. Bacteria Can Also Be Coupled to Nanomaterials Enabling Drug-Loading, Photocatalytic And/or Magnetic Properties, Using the Bacteria's Net Negative Charge. <https://doi.org/10.31219/osf.io/embqk>.
132. Moataz Dowaidar. Research into P2X Purinergic Receptor Function in Tumor Growth Has Made Substantial Progress with Potential Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/r34fs>.
133. Moataz Dowaidar. RNA Therapies Hold Great Promise for Treating Cancer. High-Throughput Screening Techniques Have Facilitated the Development of RNA Treatments. <https://doi.org/10.31219/osf.io/9vxxrb>.
134. Moataz Dowaidar. RNAi Treatment Has Been Shown to Successfully Modify Human-Related Target Gene Expression, Including Cancer. It Has the Capacity to Control Non-Standard Oncogenes, such as Oncogenic lncRNAs. <https://doi.org/10.31219/osf.io/bwqep>.
135. Moataz Dowaidar. RNAs Hold a Lot of Potential When It Comes to Druggable Molecular Targets. <https://doi.org/10.31219/osf.io/2dtxg>.
136. Moataz Dowaidar. Shadow Enhancers' Objective Seems to Be to Establish Robust Growth Patterns Independent of Genetic or Environmental Stress. <https://doi.org/10.31219/osf.io/qfnkp>.
137. Moataz Dowaidar. Sickle Cell Disease Hematopoietic Stem Cell Gene Therapy with Globin Gene Addition Is Promising. <https://doi.org/10.31219/osf.io/j5fkb>.
138. Moataz Dowaidar. Single-Gene Mutations in mtDNA-Associated Proteins Are Unlikely to Be the Main Cause of Sporadic Parkinson's Disease. Cumulative Genetic Variation in Numerous Genes May Be Important in Neurodegeneration and PD Risk. <https://doi.org/10.31219/osf.io/89qte>.
139. Moataz Dowaidar. Small Nuclear Ribonucleoproteins (snRNPs) Based Gene Therapy. <https://doi.org/10.31219/osf.io/c43r9>.
140. Moataz Dowaidar. Studying the Pathologic Mechanisms of Osteoporosis and the Bone Microenvironment May Help Researchers Better Know the Etiology of Rheumatoid Arthritis, Periodontitis, and Multiple Myeloma, as Well as Other Inflammatory and Autoimmune Disorders. <https://doi.org/10.31219/osf.io/t3z6y>.
141. Moataz Dowaidar. Suicide Gene Therapy May Be Effective in the Treatment of Malignant Glioma. <https://doi.org/10.31219/osf.io/vdkst>.
142. Moataz Dowaidar. Synuclein Is a Protein That Is Expressed in Brain Tissue. The Specific Missense Mutation (SNCA) Found in a Family with Parkinson's Disease Is the Cause. Other Diseases Include Alzheimer's Disease and REM Sleep Behavior Disorder. <https://doi.org/10.31219/osf.io/bs8rc>.
143. Moataz Dowaidar. Systems Biology Is a Method for Analyzing Massive Amounts of Multidimensional Data Generated by Omics Technologies. Cross-Validation of the Various Technological Platforms Is Critical. <https://doi.org/10.31219/osf.io/p8vkd>.

144. Moataz Dowaidar. Targeting Mitochondria and Especially Taz Gene Mutation Induces CL May Give Novel Therapeutic Alternatives for Treating Barth Syndrome. <https://doi.org/10.31219/osf.io/unfpy>.
145. Moataz Dowaidar. The Ability to Combine Multiple mRNA Antigens Targeting Multiple Pathogens Simultaneously, and the Robust Immune Responses Are Confirmed in Several Clinical Studies. <https://doi.org/10.31219/osf.io/6qksx>.
146. Moataz Dowaidar. The Cubic Polyhedral Oligomeric Silsesquioxanes Based Hybrid Materials Have a Wide Variety of Applications, Including Drug Administration, Gene Therapy, Biological Imaging, and Bone Regeneration. <https://doi.org/10.31219/osf.io/9peq8>.
147. Moataz Dowaidar. The Development of Tissue Replacement Therapies and Drug Discovery Was a Critical Milestone in Advancing Regenerative Medicine. <https://doi.org/10.31219/osf.io/w9bsm>.
148. Moataz Dowaidar. The Epidemic of COVID-19 Prompted Widespread Use of mRNA Vaccinations. <https://doi.org/10.31219/osf.io/jqws5>.
149. Moataz Dowaidar. The Most Useful and Commonly Available Acute Rejection Surveillance Strategies Are Routine Monitoring of Myocardial Function and Donor-Specific Anti-HLA Abs Monitoring. <https://doi.org/10.31219/osf.io/ebw68>.
150. Moataz Dowaidar. The Protease MBTPS2 Is an Important Regulator of Several Cellular Processes, Especially in Health and Sickness. <https://doi.org/10.31219/osf.io/qyn6h>.
151. Moataz Dowaidar. The Sigma 1 Receptor (S1R) Is a Potential Therapeutic Target for the Treatment of Huntington's Disease. <https://doi.org/10.31219/osf.io/mcefx>.
152. Moataz Dowaidar. The Use of a Network Medicine Approach Might Result in Innovative Strategies for Lowering Coronary Heart Disease and CV Risks. <https://doi.org/10.31219/osf.io/eakg8>.
153. Moataz Dowaidar. The Vasoconstrictor Endothelin System Involvement in Chronic Kidney Diseases Pathogenesis Is Now the Most Often Employed Treatment Method. <https://doi.org/10.31219/osf.io/cnkqy>.
154. Moataz Dowaidar. The VPS35-D620N Mutation Is Associated with Parkinson's Disease and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/83sxx>.
155. Moataz Dowaidar. Therapeutics Including Gene Therapy for Osteoarthritis as a Concept. <https://doi.org/10.31219/osf.io/7zsqy>.
156. Moataz Dowaidar. Tissue Hypoxia Has Been Established as a Master Regulator for Alternative Splicing, with Substantial Clinical Consequences and Possibilities for Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/5pbw4>.
157. Moataz Dowaidar. To Rectify Alzheimer's Disease Etiology, Excessive Mitochondrial Division Might Be Stopped or Mitophagy Might Be Promoted. <https://doi.org/10.31219/osf.io/6kdxw>.
158. Moataz Dowaidar. Transcriptomics Is a Rapidly Growing Field That Generates New Data That May Be Used on Its Own or in Combination with Existing Clinical Data for Development of New Therapeutics, Including Gene Therapy. <https://doi.org/10.31219/osf.io/kfr6a>.
159. Moataz Dowaidar. Tumor Microenvironment Has Clinical Significance in Terms of Prognosis and Therapy Prediction. <https://doi.org/10.31219/osf.io/4dz8q>.
160. Moataz Dowaidar. Using AAV as a Gene Delivery Vector in the Neural System Is Effective in Several Animals, such as Nonhuman Primates. <https://doi.org/10.31219/osf.io/ut4fa>.
161. Moataz Dowaidar. Using Pre-Existing Datasets to Combine Published Information with New Metrics Would Help Researchers Construct a Broader Picture of Chromatin in Disease. <https://doi.org/10.31219/osf.io/gsqv5>.
162. Moataz Dowaidar. Virus-like Particles Are Good Nanocarriers for Liquid Biopsy Probes, Imaging Contrast Agents, and Anticancer Medications. <https://doi.org/10.31219/osf.io/xbtka>.
163. Moataz Dowaidar. ZEB1 Controls the Expression of ICAM1, Promoting Monocyte-Macrophage Adhesion and Hence the Formation of Atherosclerotic Lesions. <https://doi.org/10.31219/osf.io/kzjqg>.
164. Moataz Dowaidar. Gene Therapy Development and Legislation. <https://doi.org/10.31219/osf.io/mwb2n>.
165. Moataz Dowaidar. Next-Generation Sequencing Is Now Utilized to Identify Genetic Abnormalities and Develop Gene Therapy. <https://doi.org/10.31219/osf.io/em7xp>.
166. Moataz Dowaidar. Nucleic Acid Designs, Artificial Intelligence for Screening Nanomaterials, and Enhanced Characterization Methods Are Needed to Make Nanomedicine More Successful. <https://doi.org/10.31219/osf.io/2w5aq>.

167. Moataz Dowaidar. Potential Strategies for Cancer Gene Therapy. <https://doi.org/10.31219/osf.io/atcqz>.
168. Moataz Dowaidar. Quantitative Groups Will Be Critical to the Success of Future Gene Therapy Programs. <https://doi.org/10.31219/osf.io/v97ht>.
169. Moataz Dowaidar. The Treatment of Major Human Illnesses with Recombinant Adeno-Associated Virus (rAAV) Has Shown Tremendous Promises. <https://doi.org/10.31219/osf.io/uwa4e>.
170. Moataz Dowaidar. Carbon Nanotubes Have Enormous Potential in Gene Therapy. <https://doi.org/10.31219/osf.io/9bcxk>.
171. Moataz Dowaidar. Charge-Alteration-Based Approaches Can Address the Evolving Needs of Nucleic Acid-Based Gene Therapy, Charge Reversal Techniques Are Also Promising. <https://doi.org/10.31219/osf.io/zwq5h>.
172. Moataz Dowaidar. Chromosome X, the Most Explored Genome-Editing Chromosome, Presents Possibilities for Hemophilia A Treatments. <https://doi.org/10.31219/osf.io/6vsdz>.
173. Moataz Dowaidar. Clinical Investigations Show That siRNA May Be Used to Treat a Variety of Disorders, Including Cancer. <https://doi.org/10.31219/osf.io/fcsgq>.
174. Moataz Dowaidar. Cyclodextrins as Potential Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zhtsc>.
175. Moataz Dowaidar. Development of Specialized Carriers Capable of Delivering Effective RNAi and siRNA Gene Therapy. <https://doi.org/10.31219/osf.io/3ykwmm>.
176. Moataz Dowaidar. Gene Therapy Can Target Mutations such as BRAF, Which Have Been Shown to Make Tumors More Susceptible to Autophagy Suppression. <https://doi.org/10.31219/osf.io/3gwra>.
177. Moataz Dowaidar. Gene Therapy Vectors Should Enable CRISPR Systems to Accumulate at Disease Sites and Successfully Penetrate Nuclei. <https://doi.org/10.31219/osf.io/xzmmnc>.
178. Moataz Dowaidar. Nanoformulations Can Be Utilized to Deliver Effective siRNA to Tumor Cells to Decrease Gene Expression. <https://doi.org/10.31219/osf.io/zvukc>.
179. Moataz Dowaidar. Neuronal Ceroid Lipofuscinosis Therapeutics. <https://doi.org/10.31219/osf.io/75vcp>.
180. Moataz Dowaidar. Nonviral Gene Delivery Vectors for Transfection of the CAR Gene for CAR-T Cell Therapy. <https://doi.org/10.31219/osf.io/ckxh5>.
181. Moataz Dowaidar. Potential HIV Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/e5hm2>.
182. Moataz Dowaidar. Research on Cell Sources for Brain Cell Replacement Methods Has Gained Major Importance. Cell and Gene Therapy Are Potentially Intriguing New Domains of Regenerative Medicine. <https://doi.org/10.31219/osf.io/g835b>.
183. Moataz Dowaidar. RNAi-Based Gene Therapy Provides a Wide Variety of Applications. Safe, Biodegradable Nano Delivery Vectors Are Still Needed. <https://doi.org/10.31219/osf.io/s2zhn>.
184. Moataz Dowaidar. Strategies for Treating Multiple Sclerosis with Gene Therapy. <https://doi.org/10.31219/osf.io/sync6>.
185. Moataz Dowaidar. The Combination of Unique Biomolecules and Nanoparticles Has Shown Successful Gene Therapy Treatment Approaches for Non-Small Cell Lung Cancer Treatment. <https://doi.org/10.31219/osf.io/yeq5z>.
186. Moataz Dowaidar. Understanding Why the Same Gene Delivery Vector Behaves Differently in Different Cell Types Is Essential for Developing More Adaptable Transfection Systems. <https://doi.org/10.31219/osf.io/6q8af>.
187. Moataz Dowaidar. AAV9 Is Considered the Most Efficient AAV Serotype Targeting Blood-Brain Barriers. To Enhance Effective Gene Therapy for CNS Illnesses, Testing Novel Vectors with More Efficient Crossing Capabilities Is Vital. <https://doi.org/10.31219/osf.io/7bf5s>.
188. Moataz Dowaidar. Artificial miRNAs Are Potential Gene Therapy Tools, Especially for Incurable Monogenic Disorders. <https://doi.org/10.31219/osf.io/d5nm>.
189. Moataz Dowaidar. Breakthroughs in mRNA Modification and Nanoparticle-Based Delivery Vehicles Facilitate Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/ky7dt>.
190. Moataz Dowaidar. CRISPR/Cas9-Mediated Genome Editing Has Demonstrated Significant Promise for Genetic Correction in Autologous Hematopoietic Stem/progenitor Cells (HSPCs) and Induced Pluripotent Stem Cells (iPSCs). <https://doi.org/10.31219/osf.io/xk54r>.
191. Moataz Dowaidar. Gene Therapy Vectors for Targeting the Heart. <https://doi.org/10.31219/osf.io/gcbhf>.

192. Moataz Dowaidar. Liposomes Can Minimize Cardiotoxicity, Address Drug Resistance, and Improve Overall Drug Release Profiles in Breast Cancer. <https://doi.org/10.31219/osf.io/tn56d>.
193. Moataz Dowaidar. Liposomes with Cerasome-Forming Lipids as Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zjn6v>.
194. Moataz Dowaidar. Nanomaterials Combine Multiple Therapeutic Approaches for Cancer Cell Multidrug Resistance, Ferroptotic Cell Death Is Promising in Various Cancers. <https://doi.org/10.31219/osf.io/7bg9t>.
195. Moataz Dowaidar. Nanomedicines for Enhanced Permeability and Retention (EPR)-Stratified Patients Have the Potential to Improve Treatment Outcomes. <https://doi.org/10.31219/osf.io/xrcb2>.
196. Moataz Dowaidar. RNA-Based Gene Therapy for Manipulating the Neuroinflammatory Cascade Closely Linked to Neurodegeneration Can Help Reduce Disease Development. <https://doi.org/10.31219/osf.io/2hswv>.
197. Moataz Dowaidar. Targeted Chemical Nucleases Have a Wide Range of Untapped Applications in Biological Fields, Including Gene Therapy. <https://doi.org/10.31219/osf.io/6bexs>.
198. Moataz Dowaidar. Bacterial Nanoparticles Can Deliver Proteins, Medications, Enzymes, and Genes to Diagnose and Cure Numerous Illnesses. <https://doi.org/10.31219/osf.io/7gyna>.
199. Moataz Dowaidar. Exosomal miRNA Diagnostic and Gene Therapy Tools. <https://doi.org/10.31219/osf.io/aknrc>.
200. Moataz Dowaidar. Gene Modification Research Has Potential, from Diagnostic to Therapeutic Levels. The Most Promising Metabolic Pathways Include the TGF-1 Signaling System, Inflammation and Protein Transport. <https://doi.org/10.31219/osf.io/5ert4>.
201. Moataz Dowaidar. Gene Therapy Using MnO₂ Nanoparticles. <https://doi.org/10.31219/osf.io/xmwjs>.
202. Moataz Dowaidar. Gene-Regulatory Elements May Change the Amount, Timing, or Location of Gene Expression, Cis-Regulation Therapy Platforms Might Become a Gene Therapy to Treat Many Genetic Diseases. <https://doi.org/10.31219/osf.io/x5a2>.
203. Moataz Dowaidar. Hemophilia Therapeutics. <https://doi.org/10.31219/osf.io/gu74x>.
204. Moataz Dowaidar. Mesenchymal Stem Cells Strategies in Cancer Immunotherapy. <https://doi.org/10.31219/osf.io/dkv6w>.
205. Moataz Dowaidar. Nanomaterials Can Inhibit Planktonic and Biofilm Bacteria and Can Be Used as Topical Therapy for Mouth and Wound-Related Infections. <https://doi.org/10.31219/osf.io/aqd2e>.
206. Moataz Dowaidar. New Technologies to Improve CAR T Cell Generation and Biomanufacturing Will Lead to Safer, More Therapeutically Effective Cells. <https://doi.org/10.31219/osf.io/un8gp>.
207. Moataz Dowaidar. Ocular Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/7en3k>.
208. Moataz Dowaidar. Peripheral Nerve Injury Therapeutics, Including Electrical Stimulation, Stem Cell Treatments, and Synthetic Neural Scaffolds, Have Shown Promising Preclinical and Even Clinical Results with Potential Regenerative Treatment. <https://doi.org/10.31219/osf.io/m8cs9>.
209. Moataz Dowaidar. Photothermal and Photodynamic Photoactivation of Nanomaterials-Based Prodrugs Are Two Key Methods for NIR Light-Mediated Photoactivation. <https://doi.org/10.31219/osf.io/2bh3r>.
210. Moataz Dowaidar. Quantum Dots Have the Potential to Be Used in Gene Therapy. <https://doi.org/10.31219/osf.io/bdeg6>.
211. Moataz Dowaidar. Sickle Cell Disease Has Emerged as a Public Health Concern. Some Drugs May Conflict with Curative Therapies, yet They May Be Useful as a Bridge to HSCT and Gene Therapy. <https://doi.org/10.31219/osf.io/6kufh>.
212. Moataz Dowaidar. Stimulator of Interferon Genes (STING)-Activating Nanoparticles Can Be Employed as a Tool for Controlled Immune Activation. <https://doi.org/10.31219/osf.io/2ez7a>.
213. Moataz Dowaidar. CRISPR/Cas9 Has Introduced New Gene Therapy Possibilities for Muscular Dystrophies. <https://doi.org/10.31219/osf.io/ug8v4>.
214. Moataz Dowaidar. Degradable Branched Polycationic Systems Are Promising Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/utypf>.
215. Moataz Dowaidar. Developing Nanotechnology Platforms for Peptide-Based Combinatory Cancer Gene Therapy Will Likely Have a Significant Influence on the Development of Personalized Cancer Medicines. <https://doi.org/10.31219/osf.io/zbrkj>.

- 216.Moataz Dowaidar. Exosomes May Prevent Cardiac Attacks, Heart Failure, and Cardiomyopathy. <https://doi.org/10.31219/osf.io/agm3k>.
- 217.Moataz Dowaidar. 2021gr. Exosomes Potential Therapeutics. <https://doi.org/10.31219/osf.io/mhwt3>.
- 218.Moataz Dowaidar. Gene Therapy Using miRNA Treatment Suppresses the Expression of Bone-Forming Defective Genes and Raises the Expression of Genes That Become Dormant during Bone Building. <https://doi.org/10.31219/osf.io/tcka3>.
- 219.Moataz Dowaidar. Genome-Editing Is Promising for Producing Therapeutically Relevant Animal Models for Possible Therapies for Rare Human Diseases. <https://doi.org/10.31219/osf.io/dehr9>.
- 220.Moataz Dowaidar. Human Corneal Endothelial Cells Grafts to Replace Cadaveric Donor Corneas. <https://doi.org/10.31219/osf.io/p9x7e>.
- 221.Moataz Dowaidar. Hybrid Nanotechnology and Peptide Nucleic Acid Could Improve the Effectiveness of Gene Therapy by Increasing Its Cell Permeability. <https://doi.org/10.31219/osf.io/d8wzt>.
- 222.Moataz Dowaidar. In Prenatal Stem Cell Transplantation and in Utero Gene Therapy, a Wide Spectrum of Genetic Diseases Can Be Diagnosed and Treated before Birth. <https://doi.org/10.31219/osf.io/sa3vz>.
- 223.Moataz Dowaidar. Magnetic Iron Oxide Nanoparticles Have Potential on Gene Therapy Effectiveness and Biocompatibility. <https://doi.org/10.31219/osf.io/f3hm4>.
- 224.Moataz Dowaidar. Neurotrophin Gene Therapy May Be Able to Treat Individuals with Noise-Induced Hearing Loss or Neural Presbycusis. <https://doi.org/10.31219/osf.io/spkxh>.
- 225.Moataz Dowaidar. Plant Viral Nanoparticles Can Be Used in Biological Systems for Loading and Transporting Cargo. <https://doi.org/10.31219/osf.io/txdka>.
- 226.Moataz Dowaidar. Polydopamine May Be Easily Functionalized with a Range of Nanomaterials for Synergistic Cancer Therapy, in Addition to Its Exceptional Photothermal Effects. <https://doi.org/10.31219/osf.io/cq942>.
- 227.Moataz Dowaidar. Tumor-Targeted Drug Delivery Systems for Anticancer Therapies Can Selectively Provide an Appropriate Cytotoxic Payload to Cancer Cells, Reducing the Side Effects of Chemo. <https://doi.org/10.31219/osf.io/683nj>.
- 228.Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Krista Freimann, Kaido Kurrikoff, Xiaodong Zou, and Ülo Langel. 2017. Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. *Scientific Reports* 7 (1): 9159. <https://doi.org/10.1038/s41598-017-09803-z>.
- 229.Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Supplemental Material for Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles–cell-Penetrating Peptide. *SAGE Journals*. <https://doi.org/10.25384/SAGE.7105436.V1>.
- 230.Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Xiaodong Zou, and Ülo Langel. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery General Subjects. *Biochimica et Biophysica Acta, General Subjects*. <https://pubag.nal.usda.gov/catalog/5734174>.
- 231.Moataz Dowaidar. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery. *Biochimica et Biophysica Acta, General Subjects* 1861 (9): 2334–41. <https://doi.org/10.1016/j.bbagen.2017.07.002>.
- 232.Dowaidar, Moataz, and Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis.
- 233.Moataz Dowaidar. Addiction Biology Research on miRNAs, and Their Role in the Pathophysiology of Addiction Is Enabling Gene Therapy Opportunities. <https://doi.org/10.31219/osf.io/z5wyt>.
- 234.Moataz Dowaidar. Aptamers Targeting Vascular Endothelial Growth Factor Molecular Regulation as Potential Therapists. <https://doi.org/10.31219/osf.io/a8qpr>.
- 235.Moataz Dowaidar. Arrhythmogenic Cardiomyopathy Is a Set of Hereditary Cardiac Muscle Disorders Where Various Etiologies Converge. Most ACM Patients Do Not Have a Genetic Diagnosis. <https://doi.org/10.31219/osf.io/pztv3>.
- 236.Moataz Dowaidar. Autophagy, Immunological Response, and Inflammation All Rely on the TRIM Family Proteins. TRIM-Based Therapeutics for Inflammatory Illnesses Including Diabetes and Diabetic Comorbidities Are Promising. <https://doi.org/10.31219/osf.io/y4g6e>.

237. Moataz Dowaidar. Biogenic Particles Can Be Multiantigenic, Immunostimulative and Activate Innate Immunity While Suppressing Tumor Development. <https://doi.org/10.31219/osf.io/q2kby>.
238. Moataz Dowaidar. Biological Medications for Interventional Pain Have a Lot of Clinical Data behind Them. It Is Fair to Assume They Will Replace Steroid-Based Interventional Techniques, Providing Patients with Longer Relief. <https://doi.org/10.31219/osf.io/4y5fm>.
239. Moataz Dowaidar. Carbon Nanofibers Assist in the Manufacture of Prosthetic Joints, Promote Tissue, Organ, Nerve Regeneration and Development, and Improve Anticancer Therapy Impact and Chemosensitization for a Range of Tumor Types. <https://doi.org/10.31219/osf.io/z3ucn>.
240. Moataz Dowaidar. Emerging Therapy Options May Help Patients with RAG Deficiency, Especially Those with Severe Immune Dysregulation. <https://doi.org/10.31219/osf.io/v5tjg>.
241. Moataz Dowaidar. Exosomes as Promising Gene Therapy Tools Still Need to Be Researched and Manufactured More Efficiently. <https://doi.org/10.31219/osf.io/nw4z7>.
242. Moataz Dowaidar. Focus on Exosomes Could Help Make the Use of Circulating miRNA as Biomarkers More Practical. A Detailed Understanding of miRNA Behavior Should Be a Subject of Gene Therapy. <https://doi.org/10.31219/osf.io/uan6x>.
243. Moataz Dowaidar. Gene-Free Viral-like Particles (VLPs) Offer a Safer Alternative to Inactivating or Weakening Viral Strains for Traditional Vaccines. VLP-Based Vaccinations without Adjuvants Have Been Found to Promote Humoral and Cellular Immunity. <https://doi.org/10.31219/osf.io/9dvut>.
244. Moataz Dowaidar. Given the Importance of mTOR Signaling in a Number of Illnesses, It Looks Suitable to Use miR 99 Family Members as a Therapeutic Intervention to Deal with These Illnesses by Using Gene Therapy Tools. <https://doi.org/10.31219/osf.io/8cwgh>.
245. Moataz Dowaidar. HMGB1 Has Sparked a Lot of Attention as a Model DAMP Molecule Involved in Inflammation, Inflammatory Diseases, and Cancer. <https://doi.org/10.31219/osf.io/5qx36>.
246. Moataz Dowaidar. Nucleic Acid Nanocarriers Can Be Programmable, Spatially Adjustable and Biocompatible, Minimizing Systemic Toxicity and Improving Pharmacodynamics. <https://doi.org/10.31219/osf.io/wr237>.
247. Moataz Dowaidar. Osteoporosis Is a Prominent Source of Morbidity and Mortality in the Elderly, Particularly in Postmenopausal Women. Long Noncoding RNAs (lncRNAs) Have Been Found to Be Important Regulators and Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ghfpt>.
248. Moataz Dowaidar. Polycomb Genes Role in Cancer Pathophysiology Is Offering Targets for Therapeutics Including Gene Therapy. <https://doi.org/10.31219/osf.io/sfvej>.
249. Moataz Dowaidar. RNA Sequencing and Microarray Analysis Are Helpful Techniques to Detect Obesity-Related lncRNAs. lncRNA Can Alter Cholesterol Metabolism and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/3fb6w>.
250. Moataz Dowaidar. Sepsis-Associated Acute Kidney Damage Is a Disease That Affects the Patient's Quality of Life. It Should Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/49k7q>.
251. Moataz Dowaidar. The Gene Expression Profiling Gives an in-Depth Insight of Breast Cancer Heterogeneity, Better than a Single Protein or Gene Expression. It Is Time to Include It in the Daily Routine. <https://doi.org/10.31219/osf.io/xhyd7>.
252. Moataz Dowaidar. The Nanomedicine System Has Successfully Inhibited Tumor Neovascularization Using Gene Silencing, Chemotherapy, Photothermal Therapy, and Other Therapies. <https://doi.org/10.31219/osf.io/rk2bf>.
253. Moataz Dowaidar. The Therapeutic Application of a Nucleic Acid Sequence to Patients' Diseased Organs Is Currently Available. <https://doi.org/10.31219/osf.io/pqsbfb>.
254. Moataz Dowaidar. Triple-Negative Breast Cancer, Which Lacks the Expression of Hormone Receptors and HER2, Has a Worse Prognosis. Massive Parallel Sequencing Is Capable of Reliably Breaking down the Intra-Tumor and Inter-Tumor Heterogeneity. <https://doi.org/10.31219/osf.io/pvk7u>.
255. Dowaidar, Moataz, H. A. Ismail, A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.

256. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-Cell-Penetrating Peptide. *Journal of Biomaterials Applications* 33 (3): 392–401. <https://doi.org/10.1177/0885328218796623>.
257. Dowaidar, Moataz, and Ahmad Settin. 2010. Risk of Myocardial Infarction Related to Factor V Leiden Mutation: A Meta-Analysis. *Genetic Testing and Molecular Biomarkers* 14 (4): 493–98. <https://doi.org/10.1089/gtmb.2010.0017>.
258. Gestin, Maxime, Moataz Dowaidar, and Ülo Langel. 2017. Uptake Mechanism of Cell-Penetrating Peptides. *Advances in Experimental Medicine and Biology* 1030: 255–64. https://doi.org/10.1007/978-3-319-66095-0_11.
259. Ismail, H. A., A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
260. Settin, Ahmad A., Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2009. Methylene Tetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms Related to Overweight/obesity among Saudi Subjects from Qassim Region. *Disease Markers* 27 (2): 97–102. <https://doi.org/10.3233/DMA-2009-0660>.
261. Settin, Ahmad A., Abdullah Alghasham, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012. Frequency of Thrombophilic Genetic Polymorphisms among Saudi Subjects Compared with Other Populations. *Hematology* 17 (3): 176–82. <https://doi.org/10.1179/102453312X13376952196575>.
262. Settin, Ahmad, Ibrahim S. Abu-Saif, Rizk El-Baz, Moataz Dowaidar, Rabab Abu-Al Kasim, and Shaimaa Shabana. 2007a. Diagnosis of Sex Chromosome Disorders and Prenatal Diagnosis of Down Syndrome Using Interphase Fluorescent In-Situ Hybridization Technique. *International Journal of Health Sciences* 1 (2): 203–9. <https://www.ncbi.nlm.nih.gov/pubmed/21475429>.
263. Settin, Ahmad, Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2011. Methylene Tetrahydrofolate Reductase (MTHFR) and Angiotensinogen Converting Enzyme (ACE) Gene Polymorphisms Related to Overweight and Obesity among Saudi Patients in Al Qassim. *International Journal of Health Sciences* 5 (2 Suppl 1): 24–25. <https://www.ncbi.nlm.nih.gov/pubmed/23284565>.
264. Settin, Ahmad, Hala Almarsafawy, Ahmad Alhussieny, and Moataz Dowaidar. 2008a. Dysmorphic Features, Consanguinity and Cytogenetic Pattern of Congenital Heart Diseases: A Pilot Study from Mansoura Locality, Egypt. *International Journal of Health Sciences* 2 (2): 101–11. <https://www.ncbi.nlm.nih.gov/pubmed/21475491>.
265. Settin, Ahmad, Moataz Dowaidar, Rizk El-Baz, Ayman Abd-Al-Samad, Ibrahim El-Sayed, and Mahmoud Nasr. 2008. Frequency of Factor V Leiden Mutation in Egyptian Cases with Myocardial Infarction. *Hematology* 13 (3): 170–74. <https://doi.org/10.1179/102453308X316158>.
266. Venit, Tomas, Moataz Dowaidar, Maxime Gestin, Syed Raza Mahmood, Ülo Langel, and Piergiorgio Percipalle. 2020. Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to Be Part of a Common Response to Cell-Penetrating Peptides. *Biomolecules* 10 (11): 1567. <https://doi.org/10.3390/biom10111567>.
267. Dowaidar, M. Cell-Penetrating Peptides Uptake Pathways and Role in Drug Delivery with Potentials for Gene Therapy and Vaccine Development . *Preprints.org* 2023, 2023070889. <https://doi.org/10.20944/preprints202307.0889.v1>